Negotiating Medicare drug prices is a first after Congress previously banned it, potentially leading to lower costs for over 50 million seniors.
The Inflation Reduction Act allows for negotiations on up to 20 drugs by the end of the decade, focusing on high-cost medications of significant spending.
Medicare Part D spends billions on drugs, mostly on a small percentage, prompting a focus on negotiating prices for medicines with the highest program costs.
Collection
[
|
...
]